Blog

Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar’s orphan indication products, resulting in non-dilutive funding for Jaguar

SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced the voting results of the Company’s Annual Meeting of Stockholders held on August 19, 2025 (the “Annual Meeting”).

Seven proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A relating to the Annual Meeting and supplemental information filed with the Securities and Exchange Commission on July 21, 2025 and as amended on August 6, 2025. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company’s corporate website.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Jaguar management will present at the August 2025 Emerging Growth Conference, and statements regarding Jaguar’s planned regulatory pathway to complete a supplemental NDA for crofelemer for patients with metastatic breast cancer. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Trusted firearms retailer and training center offers entrepreneurs a rare chance to own a piece of its legacy.

ORLANDO, FL / ACCESS Newswire / August 19, 2025 / Rieg’s Gun Shop & Shooting Range, a family-founded business serving firearm owners since 1968, has announced the launch of its first-ever franchise program.

Known for its strong brand recognition, comprehensive training, and proven business model, Rieg’s is opening franchise opportunities to qualified entrepreneurs with a passion for firearms and a commitment to responsible ownership.

Franchisees will benefit from:

• A 2-week hands-on training program

• Established supply chain and exclusive territories

• Multiple revenue streams including retail, range fees, classes, and rentals

• Ongoing support from industry veterans

“The firearm industry is booming, and our franchise partners will enter the market backed by a respected name and over five decades of experience,” said Justin Hilton

According to the NSSF, over 26 million new gun owners have entered the U.S. market since 2020, fueling growth in an industry that generated $91.65 billion in 2024.

Contact:

Justin Hilton
Email: Franchise@TheRiegs.com
Office: 407.473.0869

SOURCE: Rieg’s Gun Shop & Range

View the original press release on ACCESS Newswire

LOS ANGELES, CA / ACCESS Newswire / August 19, 2025 / ClaimNotify.org, a new online tool and educational hub for all things unclaimed assets, launched today to help Californians easily navigate the complex world of abandoned assets. With a mission to become the trusted national resource, the platform empowers residents to recover funds and assets that rightfully belong to them.

Unclaimed assets- ranging from forgotten bank accounts and uncashed checks to insurance benefits and safe deposit box contents- are currently valued at over $2.5 billion in Los Angeles County and $600 million in San Diego County, according to recent public notices. Until now, finding and reclaiming these funds has been a confusing and time-consuming process.

The launch comes at a pivotal moment: on September 4, 2025, new California code changes- driven by the passage of SB 822, which expands the state’s Unclaimed Property Law to include digital financial assets- will make it easier for residents to submit claims online. ClaimNotify.org will offer up-to-the-minute guidance on these changes, ensuring no eligible Californian misses their opportunity to reclaim what’s theirs.

ClaimNotify.org streamlines the journey, offering:

• A Centralized Resource for Californians: One place to access news, updates, and verified links for unclaimed asset searches, starting with California and expanding to other states.

• Educational Tools: Easy-to-follow guides explaining what unclaimed assets are, how they get lost, and how residents can submit claims.

• Breaking Updates: Timely alerts on new policies, large asset disclosures, and deadlines for filing claims.

• Step-by-Step Support: Clear instructions to help users submit claims directly, without costly third-party services.

“Unclaimed assets can be life-changing, but most people don’t even realize they exist- let alone how to recover them,” said a ClaimNotify.org spokesperson. “Our goal is to be the go-to source for accurate, accessible, and timely information, so Californians can claim what’s theirs without unnecessary stress or confusion.”

Claim Notify plans to expand its coverage to include news and resources from multiple states, helping Americans nationwide access the billions in unclaimed property sitting in government coffers.

To view the resources and learn more, visit: Claimnotify.org

About ClaimNotify.org
ClaimNotify.org is a public information portal dedicated to helping individuals navigate the often-confusing process of recovering unclaimed property. By consolidating updates, official resources, and step-by-step guides, ClaimNotify.org empowers people to reclaim their money and property with confidence. For more information, visit: ClaimNotify.org

Contact:
info@claimnotify.org

SOURCE: govrecover

View the original press release on ACCESS Newswire

CHARLOTTE, NC / ACCESS Newswire / August 19, 2025 / Most Sunseeker Tech products, including the X7 Series of state-of-the-art robotic mowers, can now be purchased online as a part of the new partnership between Sunseeker Tech and Lowe’s. This partnership marks a significant step in expanding Sunseeker’s reach to more homeowners in the United States. It offers innovative solutions with its advanced lawn care machines.

“At Sunseeker, robotic lawn care is the norm, not the exception. The collaboration with Lowe’s will enable us to target more homeowners than ever before, giving them the ease, accuracy, and sustainability,” said the CEO.

Putting Smart Lawn Care in More Lawns

With the collaboration between Lowe’s and Sunseeker, the company would turn a new leaf in its quest to popularize robotic mowing as an option among housekeepers. Lowe’s is the most recognized online shopping platform in home improvement in America.

It offers the best medium to reach the tech-savvy segment of consumers eager to find sustainable and efficient form of maintaining their property. This will allow customers in Charlotte and beyond to buy robotic mowers. This ensure professional-quality results with minimum human interaction.

Features of Sunseeker X7 Series

Among the product line, X7 Series is a fully autonomous robot lawn mower designed to provide unique lawn care experience, with highly advanced AI technology, RTK (Real-Time Kinematic) navigation and high-grade engineering.

It is unique due to the following features:

• Adaptive AI Mowing Patterns: The mower learns and can adapt to growth of the grass, weather and obstacles providing smooth and consistent cutting

• RTK-level Accuracy: Operates at sub-centimeter campus-wide accuracy without the use of perimeter wires. It can reduce cost on an installation and enhance dependability

• Smart Collision Sensing: Automatically senses pets, children, and garden decor and goes around them unhindered

• All-Weather Performance: The construction is designed to work in any kind of weather with rain sensors and IPX durability rating

The electric, less noisy motor of the X7 does not only limit environmental interference but also promotes silent work. It is a vehicle-friendly in the neighborhoods. With a companion mobile app, homeowners can view, schedule, and control their mower remotely from anyplace, welcoming it to their smart home system.

High-End, Low Pressure

The mission of Sunseeker is not just a grass cutting machine but about giving back time to people. The CEO said that the target was to assist homeowners in reclaiming their weekends. You will never have to worry about your lawn with Sunseeker. You can rest in knowing that you have one less thing to worry about because your lawn is well taken care of.

Whether on tightly trimmed urban gardens or expansive suburban gardens, the X7 is able to adjust to all set-ups. It can move over hills, rugged land, and different types of grasses easily. That is why it is good both in residential areas, Charlotte neighborhood, and golf resort spaces.

Making Lawn Care Futuristic

Robotic mowing has a positive impact on the world. Not only does it make life easier, but also helps create a healthier planet. When homeowners upgrade their gas mowers to battery-operated ones such as the X7, they reduce noise pollution caused by emissions.

Its smart scheduling of the mower also ensures that whether it cuts the lawn more often or less, it is healthy without any extra energy. This increased enthusiasm among consumers on eco-friendly technology that can sustain the lifestyle without sacrificing performance.

More Smarter Lawn Care

Sunseeker expects to be an entirely incorporated player in the smart home ecosystem. The company’s vision is that its mowers will interact with other smart devices and adapt intelligently to the shifts in the environment. It is also to present hyper-personalized mowing formats to the yard. As the company continues to innovate, it will continue to add more products to its line. It seeks to address the requirements of all kinds of homeowners, whether of a small city plot or large estate.

Availability

TheLowe’s online store now offers the Sunseeker robotic mowers, such as the X7 Series which is the more advanced version of their product line. Customers will have access to product specifications, models to compare, and convenience of shipping and customer services offered by Lowe’s.

To know more about the products of Sunseeker, you can visit the site www.sunseekertech.com Follow the brand on social media to get acquainted with the latest news, user experience, and views:

• Instagram: @SunseekerNA

• Facebook: SunseekerNA

• YouTube: SunseekerNA

About Sunseeker Robotic Technology

Sunseeker Robotic Technology will ensure it is a pioneer in smart yard technology recreating the outdoor living experience with the ideal totality of current robotics, AI navigation engineering, and green engineering. Its premium X7 Series robotic mower is the benchmark of accuracy, adaptability, and convenience in a robot mower. This makes it more versatile to the homeowner that cares about performance and sustainability.

Coupled with the drive to undeniably innovate and make its customers happy, Sunseeker is constantly exploring ways to automate exterior maintenance. So, people spend less time maintaining their lawns and more time enjoying them.

Media Details:
Website URL: sunseekertech.com
Company Name: Sunseeker North America
Email address: marketing.global@sunseekertech.com
Address: 4330 Matthews Indian Trail Rd STE A
Indian Trail, NC, USA 28079

SOURCE: Sunseeker North America

View the original press release on ACCESS Newswire

The new relationship brings extensive experience to elevate client offerings and support future growth

PHILADELPHIA, PA / ACCESS Newswire / August 19, 2025 / Commonwealth M&A, LLC, a premier full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium sized businesses, today announced that Joe DiGiacomo has joined the team as a Senior Advisor and Managing Director. DiGiacomo will play a key role in company operations managing specific transactions, and will also offer counsel on other transactions, utilizing his 40+ years of experience to ensure deals close smoothly, companies get the valuation they deserve, and sellers are optimized to secure the best transition for their business.

A seasoned professional who is well-established in the lower middle market, DiGiacomo has a diverse background in investment banking, business valuation, accounting, and mergers and acquisitions. Most recently as the Founder and President of D5 Capital Advisors, a boutique lower middle market M&A advisory firm headquartered in the Lehigh Valley, as well as previous positions as the President and CFO of a $135 million multimodal transportation and logistics business, and Partner of a regional CPA firm.

“Our goals for Commonwealth M&A have been big from the start and bringing Joe on our team is going to supercharge our capabilities,” said Rick Calabrese, co-founder of Commonwealth M&A. “Having previously worked with Joe in my capacity as a transactional attorney, I know first hand the wealth of knowledge and experience he brings to the table. We are excited to add his expertise to our team to continue to bring our clients exceptional results, which is always our top priority.”

“When I was considering combining my practice with another firm, I knew I wanted to join a team that was talented and motivated. I had worked with Rick in the past and when I found out he had started his own firm, I immediately wanted to learn more. I met with him and Joe [Bergin] and the pieces just fell into place, their mindset and business approach is exactly what I was looking for,” commented Joe DiGiacomo. “This team knows what they’re doing and I really think that their energy and technical experience paired with my background is going to be a dynamic offering. I’m very excited about this new chapter and know there’s an extremely bright future ahead for Commonwealth M&A.”

In the last calendar year alone, Commonwealth M&A has closed more than $50M in transaction value for clients. Founders Rick Calabrese and Joe Bergin both offer unique expertise, Calabrese as a transactional attorney and CPA, and Bergin with a decade of corporate M&A experience at Johnson & Johnson. The team believes they can leverage DiGiacomo’s broad expertise to help lower middle market businesses find a deal that fits all of their needs.

About Commonwealth M&A, LLC
Commonwealth M&A, LLC is a full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium-sized businesses. Commonwealth M&A offers a differentiated approach derived from the team’s diverse set of experiences. Our mission is to deliver personalized, high-quality service that exceeds expectations. Visit us at https://commonwealthmna.com/

Media Contact
Martina Corona
Martina@notablypr.com

SOURCE: Commonwealth M&A

View the original press release on ACCESS Newswire

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago

SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company’s ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo’s Scientific Advisory Board will join Napo and Jaguar representatives at the meeting.

“We’re very pleased that Napo has been granted a meeting with the FDA to discuss Napo’s development plans for crofelemer for MVID – a devastating pediatric disease characterized by severe malabsorption that requires life-sustaining parenteral support to meet the nutritional, fluid and electrolyte requirements of the child, and for which there no approved drug treatments,” said Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board. “A core Napo goal for this meeting is to obtain input from the FDA on the clinical program and potential expedited regulatory pathways for this rare orphan indication.”

As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, the initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) of a novel crofelemer powder formulation for oral solution in Abu Dhabi in the United Arab Emirates show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27%. An abstract describing the initial results of this trial has been accepted for presentation at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.

Jaguar, through Napo, is supporting the independent proof-of-concept IIT in pediatric intestinal failure (IF) patients at Sheikh Khalifa Medical City in Abu Dhabi, and is conducting the placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients with IF at sites in the U.S., European Union, and Middle East/North Africa regions under appropriate regulatory approvals in each of these geographies.

“Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval,” said Lisa Conte, Jaguar’s Founder and CEO.

Based on the initial findings from the IIT in Abu Dhabi, crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Napo personnel will meet with the FDA to discuss Napo’s development plans for crofelemer for MVID, statements regarding Jaguar’s expectation that an abstract describing the results of the investigator-initiated trial in Abu Dhabi will be presented at NASPGHAN 2025, Jaguar’s expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval, and Jaguar’s expectation that crofelemer’s paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025

MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the successful completion of the Single Ascending Dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2. The study, conducted at the Hadassah Clinical Research Center in Israel under the direction of Principal Investigator Prof. Yoseph Caraco, demonstrated a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed to date.

“Completion of the SAD portion with a favorable safety and tolerability profile is an important milestone in the clinical development of Ketamir-2,” said Prof. Yoseph Caraco, Principal Investigator of the Phase 1 study. “Importantly, no severe or clinically significant adverse effects have been observed to date, which supports continued progression into the Multiple Ascending Dose stage of the trial.”

Phase 1 Study Overview

The study- “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Centre Study of Single and Repeated Dosing of Ascending Doses, to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects“-is designed to establish the safety, tolerability, and pharmacokinetics of Ketamir-2 in healthy adult volunteers.

• Design: Single-center, randomized, double-blind, placebo-controlled SAD/MAD with sentinel dosing and Safety Steering Committee (SSC) reviews between cohorts.

• SAD completed: Four cohorts (single doses 50 mg to 600 mg); 32 participants treated (male and female).

• Safety monitoring: Extensive central nervous system (CNS) safety assessments were performed using well-validated clinical research tools:

  • Columbia-Suicide Severity Rating Scale (C-SSRS) – screens for suicidal ideation or behavior, supporting early detection of potential mood or psychiatric changes.

  • Bowdle Visual Analogue Scale (VAS) – measures possible psychedelic or dissociative effects sometimes seen with ketamine and related compounds.

  • Ketamine Side Effect Tool (KSET) – tracks a broad range of known ketamine-related side effects over time, including sensory, cognitive, and mood changes.
    These tools provided multiple, complementary layers of safety evaluation to help detect even subtle CNS effects throughout the trial.

• Status: To date, no severe or clinically significant adverse effects have been observed at any dose level in the SAD portion of the study.

While the study remains ongoing and blinded, it is worth noting that, across the pharmaceutical industry as a whole, approximately one-third of investigational drugs fail during Phase 1 due to safety concerns (Tufts Center for the Study of Drug Development). These interim observations provide encouraging context as MIRA advances Ketamir-2 through the next stage of clinical evaluation, consistent with the Company’s mission to prioritize safety in every step of development.

The Company is advancing to the Multiple Ascending Dose (MAD) portion, which will evaluate three cohorts receiving daily oral doses of 150 mg, 300 mg, or 600 mg for five consecutive days in up to 24 participants.

“The emerging human safety profile complements the preclinical data we’ve generated, which show Ketamir-2’s superior efficacy in multiple neuropathic pain models without triggering the hallmark CNS side effects of ketamine,” said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA. “This combination of efficacy, safety, and oral delivery positions Ketamir-2 as a promising next-generation treatment for neuropathic pain and potentially other CNS disorders.“

Strategic & Commercial Potential

Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor (PCP site) with low affinity and shows no significant off-target activity across a broad receptor panel. Preclinical studies have demonstrated superior performance versus ketamine, pregabalin, or gabapentin (depending on comparator and model) in gold-standard neuropathic pain models-without the dissociative effects associated with ketamine.

Neuropathic pain affects an estimated 36-51 million people in North America and represents a multi-billion-dollar market today, with long-term growth driven by diabetes prevalence, cancer survivorship, and aging-related nerve damage. MIRA intends to submit a Phase 2a clinical protocol in neuropathic pain by year-end 2025 and continue evaluating potential applications in depression, anxiety, PTSD, and localized pain, subject to ongoing results and regulatory feedback.

“We are pleased to see our Phase 1 program progress as planned,” said Erez Aminov, CEO of MIRA. “Advancing into the MAD stage is an important operational step as we continue to build a rigorous safety and PK foundation for Ketamir-2 and work to deliver a differentiated, non-opioid option for patients with neuropathic pain.“

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

For more information, please visit www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire